17 May 2024
Freshfields Advises Novartis on its Exclusive License Agreement with Arvinas for a Potential first-in-class Prostate Cancer Treatment
Advising firms
Deal team
8 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Adam Golden Lead | Freshfields | Partner | Not stated | Not stated |
| Sora Park | Freshfields | Associate | Not stated | Not stated |
| Shannon O'Hara | Freshfields | Associate | Not stated | Not stated |
| Madeleine Tavcar | Freshfields | Associate | Not stated | Not stated |
| Tanny Kang | Freshfields | Associate | Not stated | Not stated |
| Jan Rybnicek | Freshfields | Partner | antitrust | Not stated |
| Meytal McCoy | Freshfields | Counsel | antitrust | Not stated |
| Emily Strickland | Freshfields | Associate | antitrust | Not stated |
5 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 150m ($150 million)
- What the figure measures
- Total transaction value
- Client
- NovartisBuy-side
- Counterparties
- Arvinas, Inc. (Sell-side)